Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis.

The Journal of infectious diseases - 16 Dec 2024

Strizki Julie M, Diamond Tracy L, Teal Valerie L, Gilbert Christopher L, Wang Weiwen, Stauffer Nicole, Haber Barbara A

Abstract excerpt

BACKGROUND: In a phase 3 trial, letermovir was noninferior to valganciclovir for cytomegalovirus (CMV) disease prophylaxis in kidney transplant recipients who were CMV-seronegative and received kidneys from donors who were CMV-seropositive. Genotypic antiviral resistance and CMV glycoprotein B (gB) genotype are reported. METHODS: Plasma samples with detectable CMV DNA were sequenced for the presence of known...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetates
Share to Cytomegalovirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytomegalovirus Infections

Share to Drug Resistance, Viral

Share to Ganciclovir

Share to Kidney Transplantation

Share to Quinazolines

Share to Transplant Recipients

Source

Open in PubMed Open full text

Identifiers

PMID: 38853607
DOI: 10.1093/infdis/jiae287
PMCID: PMC11646593

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis.PMID 38853607Read ↗

Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients.Semantic proximity Read ↗

Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.Semantic proximity Read ↗

Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.Semantic proximity Read ↗

Revealing the Unseen: Next-Generation Sequencing for Early Detection of Drug-Resistant Cytomegalovirus Variants Upon Letermovir Prophylaxis FailureSemantic proximity Read ↗

Drug-resistant cytomegalovirus: clinical implications of specific mutations.Semantic proximity Read ↗

Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.Semantic proximity Read ↗

Approach to drug-resistant cytomegalovirus in transplant recipients.Semantic proximity Read ↗

Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.Semantic proximity Read ↗

Cytomegalovirus drug resistance mutations in transplant recipients with suspected resistance.Semantic proximity Read ↗

Improvement in detecting cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance using next generation sequencingSemantic proximity Read ↗

Surveillance of CMV Terminase Gene Mutations in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir ProphylaxisSemantic proximity Read ↗

Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.